Asset
Evruleucel
Atara Biotherapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03283826 | phase1_2 | terminated | 2017-10-19 | 2023-11-09 | Atara Biotherapeutics | Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis |
FDA applications (0)
This company has no applications containing this asset.